<DOC>
	<DOCNO>NCT00021632</DOCNO>
	<brief_summary>The purpose study see treatment hepatitis C ( HCV ) patient ribavirin ( RBV ) affect anti-HIV drug stavudine ( d4T ) zidovudine ( ZDV ) . Studies show RBV may interfere action ZDV d4T . There little information way drug interact body . This study examine drug RBV affect level ZDV d4T patient currently stable anti-HIV therapy .</brief_summary>
	<brief_title>Effects Ribavirin Zidovudine Stavudine</brief_title>
	<detailed_description>RBV , nucleoside analogue , use treatment hepatitis C virus ( HCV ) alliance interferon-alfa 2a/2b patient HIV-1 . The mechanism action RBV lead vitro study examine agonism/antagonism efficacy occur use combination nucleoside reverse transcriptase inhibitor ( NRTIs ) . The primary objective pharmacology component current study evaluation effect RBV intracellular activation ZDV d4T owe report antagonism observe vitro . Pharmacokinetic ( PK ) evaluation plasma ZDV d4T intracellular ZDV d4T measurement triphosphate anabolites perform initial RBV dosing ( within 2 week visit ) 8 week RBV administration . Thymidine triphosphate ( TTP ) concentration also quantitated permit estimation ratio active drug endogenous triphosphate concentration . For entry , prior RBV dosing , blood sample collect within 2 hour prior ZDV d4T dose Hours 1 , 4 , 8 post dosing . Following entry PK blood draw , patient initiate RBV treatment within 2 week first PK study day . For Week 8 evaluation ( measure 8 week follow initiation RBV ) , blood sample collect prior ZDV d4T dose Hours 1 , 4 , 8 post dosing .</detailed_description>
	<mesh_term>Hepatitis C</mesh_term>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Ribavirin</mesh_term>
	<mesh_term>Stavudine</mesh_term>
	<mesh_term>Zidovudine</mesh_term>
	<criteria>Inclusion Criteria Patients may eligible study : Are least 13 year age . Have write consent parent guardian 18 year age . Have HIV infection . Have receive ZDV d4T least 4 week prior study entry . Are plan receive RBVcontaining hepatitis treatment doctor coenrollment another ACTG protocol within 2 week follow entry study . Have receive RBV least 6 month prior study entry previously treat RBV . Weigh 110 pound ( 50 kg ) . Exclusion Criteria Patients eligible study : Are pregnant . Use rifampin , rifabutin , pyrazinamide , isoniazid , ganciclovir , hydroxyurea within 14 day study entry . Abuse alcohol drug . Patients methadone program may participate .</criteria>
	<gender>All</gender>
	<minimum_age>13 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2013</verification_date>
	<keyword>Ribavirin</keyword>
	<keyword>Drug Interactions</keyword>
	<keyword>Drug Therapy , Combination</keyword>
	<keyword>Zidovudine</keyword>
	<keyword>Stavudine</keyword>
	<keyword>Reverse Transcriptase Inhibitors</keyword>
	<keyword>Anti-HIV Agents</keyword>
	<keyword>Pharmacokinetics</keyword>
	<keyword>Area Under Curve</keyword>
</DOC>